enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Infant respiratory distress syndrome - Wikipedia

    en.wikipedia.org/wiki/Infant_respiratory...

    Infant respiratory distress syndrome (IRDS), also known as surfactant deficiency disorder (SDD), [2] and previously called hyaline membrane disease (HMD), is a syndrome in premature infants caused by developmental insufficiency of pulmonary surfactant production and structural immaturity in the lungs.

  3. Lecithin–sphingomyelin ratio - Wikipedia

    en.wikipedia.org/wiki/Lecithin–sphingomyelin_ratio

    The lecithin–sphingomyelin ratio is a marker of fetal lung maturity. The outward flow of pulmonary secretions from the fetal lungs into the amniotic fluid maintains the level of lecithin and sphingomyelin equally until 32–33 weeks gestation, when the lecithin concentration begins to increase significantly while sphingomyelin remains nearly the same.

  4. Surfactant metabolism dysfunction - Wikipedia

    en.wikipedia.org/wiki/Surfactant_metabolism...

    Severe deficiency of pulmonary surfactant due to disturbed metabolism of any of these proteins can lead to some form of interstitial lung disease in newborns and adults. These conditions share similar pathophysiology and overlapping phenotypes because surfactant gene products interactively communicate and control one another. [ 3 ]

  5. Pulmonary surfactant - Wikipedia

    en.wikipedia.org/wiki/Pulmonary_surfactant

    Infant respiratory distress syndrome (IRDS) is caused by lack of surfactant, commonly seen in premature babies born before 28–32 weeks of gestation. [citation needed] Congenital surfactant deficiency; Pulmonary alveolar proteinosis; Surfactant metabolism dysfunction

  6. Pulmonary surfactant (medication) - Wikipedia

    en.wikipedia.org/wiki/Pulmonary_surfactant...

    Pulmonary surfactant is used as a medication to treat and prevent respiratory distress syndrome in newborn babies. [1] Prevention is generally done in babies born at a gestational age of less than 32 weeks. [1] It is given by the endotracheal tube. [1] Onset of effects is rapid. [2] A number of doses may be needed. [2]

  7. John Allen Clements - Wikipedia

    en.wikipedia.org/wiki/John_Allen_Clements

    John Allen Clements (March 16, 1923 – September 3, 2024) was an American physician and physiologist known for his role in the discovery of pulmonary surfactant, a crucial factor in the development of life-saving treatments for neonatal respiratory distress syndrome. His research revolutionized the care of premature infants, greatly reducing ...

  8. Surfactant therapy - Wikipedia

    en.wikipedia.org/wiki/Surfactant_therapy

    Surfactant therapy is the medical administration of pulmonary surfactant that is derived from outside of the body. Pulmonary surfactant is a soap-like chemical synthesized by type II alveolar pneumocytes and is of various lipids (80% phospholipids, 5-10% cholesterol, and ∼10% surfactant-associated proteins).

  9. Preterm birth - Wikipedia

    en.wikipedia.org/wiki/Preterm_birth

    Therefore, a significant overlap exists between preterm birth and prematurity. Generally, preterm babies are premature and term babies are mature. Preterm babies born near 37 weeks often have no problems relating to prematurity if their lungs have developed adequate surfactant, which allows the lungs to remain expanded between breaths. Sequelae ...